GPs prioritise specialisation, value creation in Asia - AVCJ Forum
Asian private equity has moved on from chasing momentum plays, with GPs increasingly pursuing opportunities where they have domain expertise and know they can add value, the AVCJ Private Equity & Venture Forum heard.
“Four to five years ago, if we were on this panel, people were just going to focus on what sector was the hottest or what was the hottest company and try to invest. That’s no longer the dominating...
Co-Stone leads $43m round for China biosynthesis player
Co-Stone Capital Management has led a CNY 300m (USD 43m) Series B round for Readline, a Shenzhen-based company that specialises in synthetic biology.
Australia’s Heal Partners closes debut fund on $137m
Australia’s Heal Partners, a health, education, and lifestyle-focused venture capital firm, has closed its first fund on AUD 200m (USD 137m). The target was AUD 100m.
US regulator gets access to Chinese audits
The threat of delisting that has haunted Chinese companies that trade on US exchanges appears to have receded after the US regulators announced they had gained full access to the audits of these companies for the first time.